Uma análise da dispensa pública do metilfenidato no Brasil: o caso do Espírito Santo

Caliman, Luciana Vieira; Domitrovic, Nathalia

doi:10.1590/s0103-73312013000300012

Cited by 16 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A falta de consenso acerca do diagnóstico e os efeitos colaterais, considerados nocivos, do medicamento, o qual é frequentemente utilizado, geram especulações sobre a validade e o custo dessa expansão do transtorno. Associado ao consumo crescente de metilfenidato, o TDAH é considerado um dos principais diagnósticos envolvidos nos chamados processos de farmacologização e medicalização da vida (Caliman & Domitrovic, 2013).…”

Section: Resultsunclassified

Uma crítica à produção do TDAH e a administração de drogas para crianças

Cruz

Lemos

Piani

et al. 2016

Estudos De Psicologia

View full text Add to dashboard Cite

show abstract

Section: Resultsunclassified

Uma crítica à produção do TDAH e a administração de drogas para crianças

Cruz

Lemos

Piani

et al. 2016

Estudos De Psicologia

View full text Add to dashboard Cite

show abstract

“…The associations described in the previous section, such as ABDA and Inspirare are directly and indirectly related to this configuration, either when they are invited to participate in the development of consensus and guidelines with the SUS (municipal, state and federal) management spheres or when they associate with users and family members in initiatives such as those we described throughout this article. In this second case, what is observed is that such an alliance ends up generating greater demand for medication and even judicialization of the health system (Caliman and Domitrovic, 2013 ).…”

Section: Discussionmentioning

confidence: 99%

“…The state of Espirito Santo included methylphenidate in its List of Essential Medicines (RENAME) (Espírito Santo, 2007 ) and was the first state in the country to create an ordinance regulating the public dispensation of the medication in September 2010 (Caliman and Domitrovic, 2013 ). It was followed by the municipality of São Paulo, in June 2014 (São Paulo, 2014 ) and by the city of Campinas, in October 2014 (Campinas, 2014 ).…”

Section: The Biosocial Field Of Adhd In Brazilmentioning

confidence: 99%

“…The relative autonomy of each state and municipality to define their own list of “essential medications” ensures that some medications, which until then could only be accessed by the population through lawsuits against the state, may be requested through administrative processes in SUS state pharmacies (Caliman and Domitrovic, 2013 ). Critics underline the lack of national policies for ADHD treatments and the complexity involved in granting access for procedures for low-income patients to obtain methylphenidate within SUS (by lawsuits or through an administrative process beset by red tape).…”

Section: The Biosocial Field Of Adhd In Brazilmentioning

confidence: 99%

See 1 more Smart Citation

Global Mental Health and Pharmacology: The Case of Attention Deficit and Hyperactivity Disorders in Brazil

Ortega

Müller

2020

Front. Sociol.

View full text Add to dashboard Cite

Global Mental Health (GMH) is the field of study, research, and intervention, which aims at improving access to mental health worldwide. It is based on the global burden of disease research program and on the existence of a large “treatment gap” between the need and availability of mental health services, displaying individual and social costs of undiagnosed and untreated mental disorders, especially in low- and middle-income countries (LMIC). Few academic publications in Brazil dialogue directly with the field of GMH, although several issues drawn from its agenda have been the subject of mental health policies in the country. Brazil can be classified as a middle-income country with a well-structured national health system. This system is oriented toward primary health care, which integrates both community mental health services and the broader health care network. The debate between GMH advocates and critics has unearthed old controversies in psychiatry such as universality or cultural specificity of mental disorders, their expressions, and their relationship with social and economic factors. We intend to examine how these controversies reverberate in the Brazilian mental health scenario, taking as an illustration the debates around Attention Deficit Hyperactivity Disorder (ADHD) in the country. ADHD discussions oppose those who argue that the condition is underdiagnosed and undertreated, and those who claim that there is overdiagnosis and overtreatment and thus, medicalization of childhood. This article presents the current status of the Brazilian mental health literature on ADHD, with emphasis on tensions around diagnosis, prevalence and interventions. Our aim is to highlight how the differential in discourse shapes the debate on ADHD in Brazil and how this may contribute to the GMH agenda. This goal will be undertaken in three steps. First, we will briefly examine studies around GMH and ADHD. Secondly, we address Brazilian studies on this theme, considering the specificities regarding the constitution of the mental health field. Finally, we will examine the debate of treatment gap vs. medicalization in the country in order to underscore the potentials and limitations of each perspective.

show abstract

“…Em 2000, esse valor foi elevado para 16 toneladas e, dez anos depois, a marca estatística atingiu 43 toneladas. No Brasil em 2011 foram vendidas 413 kg de MFD DOMITROVIC, 2013 (CALDEIRA, 2015). No Brasil o MFD está disponível para ser comercializado com os nomes Ritalina®, Ritalina LA® e Concerta®, todos com ingestão via oral.…”

Section: Introductionunclassified

Metilfenidato: Uma Revisão

Oliveira¹,

Moreira²,

Fonseca³

et al. 2021

Revista Científica Multidisciplinar Núcleo do Conhecimento

View full text Add to dashboard Cite

O Metilfenidato (MFD) é um medicamento derivado da anfetamina que estimula o Sistema Nervoso Central (SNC), promovendo aumento da atenção, menor distração e aumento do senso de motivação. Este estudo visa descrever as principais características farmacêuticas do MFD, destacar as indicações clínicas para o uso do MFD e detalhar os possíveis eventos adversos advindos do consumo do MFD. Para isso, realizou uma pesquisa nas bases de dados ScienceResearch.com, SciELO, LILACS, PubMed e EMBASE e nos repositórios institucionais da Universidade Federal de São Paulo, Universidade Federal de Minas Gerais e Universidade Federal do Ceará, utilizando-se das palavras-chave e associações “metilfenidato”, “ritalina”, “efeitos” e “effects”. Evidenciou-se que o fármaco consiste em uma mistura racêmica formada por quatro estereoisômeros, sendo que o composto farmacologicamente ativo é o dextrogiro do racemato (d,l)-treo-MFD. Ele age no bloqueio dos transportadores de dopamina e norepinefrina do SNC, promovendo efeitos que justificam sua prescrição para tratar Transtorno de Déficit de Atenção e Hiperatividade (TDAH). Nos últimos anos, seu consumo para fins não terapêuticos tem aumentado. Relatou-se a existência alguns efeitos adversos de seu uso, podendo citar como exemplo insônia, irritabilidade e cefaleia.

show abstract

Uma análise da dispensa pública do metilfenidato no Brasil: o caso do Espírito Santo

Cited by 16 publications

References 11 publications

Uma crítica à produção do TDAH e a administração de drogas para crianças

Uma crítica à produção do TDAH e a administração de drogas para crianças

Global Mental Health and Pharmacology: The Case of Attention Deficit and Hyperactivity Disorders in Brazil

Metilfenidato: Uma Revisão

Contact Info

Product

Resources

About